# Editas Medicine Inc. (EDIT)

Source: https://www.quantisnow.com/company/EDIT
Generated: 2026-11-11T11:48:22.293Z

- Ticker: EDIT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2016
- SEC CIK: 0001650664
- Website: editasmedicine.com

## About

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

## Latest EDIT news and filings

- 2026-11-09 21:10 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Editas Medicine Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-editas-medicine-inc-6781368)
- 2026-11-09 12:04 UTC [SEC Form 8-K] [Editas Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/editas-medicine-inc-filed-sec-form-8-k-results-of-operations-6780143)
- 2026-11-09 12:00 UTC [Earnings] [Editas Medicine Announces Third Quarter 2026 Results and Business Updates](https://www.quantisnow.com/insight/editas-medicine-announces-third-quarter-2026-results-and-business-updates-6780039)
- 2026-11-06 21:36 UTC [SEC Form 4] [EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda was granted 16,533 shares, increasing direct ownership by 27% to 78,193 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-scientific-officer-burkly-linda-was-granted-16533-shares-6779304)
- 2026-11-06 21:35 UTC [SEC Form 4] [CEO O'Neill Gilmore Neil was granted 43,567 shares, increasing direct ownership by 18% to 286,756 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-oneill-gilmore-neil-was-granted-43567-shares-increasing-direct-6779298)
- 2026-10-14 13:00 UTC [Conference Announcement] [Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference](https://www.quantisnow.com/insight/editas-medicine-announces-poster-presentations-at-the-european-society-of-6746124)
- 2026-10-08 15:16 UTC [Analyst Upgrade] [Editas Medicine upgraded by Wells Fargo with a new price target](https://www.quantisnow.com/insight/editas-medicine-upgraded-by-wells-fargo-with-a-new-price-6741472)
- 2026-10-08 11:04 UTC [SEC Form 8-K] [SEC Form 8-K filed by Editas Medicine Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-editas-medicine-inc-6741021)
- 2026-10-08 11:00 UTC [Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia](https://www.quantisnow.com/insight/editas-medicine-receives-approval-to-initiate-first-in-human-clinical-trial-of-6740984)
- 2026-09-23 12:21 UTC [Analyst Upgrade] [Editas Medicine upgraded by Guggenheim with a new price target](https://www.quantisnow.com/insight/editas-medicine-upgraded-by-guggenheim-with-a-new-price-target-6723713)
- 2026-09-09 20:58 UTC [SEC Form 4] [SEC Form 4 filed by EVP, Chief Medical Officer Ory Daniel Scott](https://www.quantisnow.com/insight/sec-form-4-filed-by-evp-chief-medical-officer-ory-6710289)
- 2026-09-09 20:24 UTC [SEC Form 3] [SEC Form 3 filed by new insider Ory Daniel Scott](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-ory-daniel-scott-6710152)
- 2026-09-09 20:21 UTC [SEC Form S-8] [SEC Form S-8 filed by Editas Medicine Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-editas-medicine-inc-6710135)
- 2026-09-09 13:00 UTC [Editas Medicine Reports Inducement Grants to New Chief Medical Officer](https://www.quantisnow.com/insight/editas-medicine-reports-inducement-grants-to-new-chief-medical-officer-6709536)
- 2026-09-09 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Editas Medicine Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-editas-medicine-inc-6709042)
- 2026-09-08 11:00 UTC [Leadership Update] [Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer](https://www.quantisnow.com/insight/editas-medicine-appoints-dan-ory-md-as-chief-medical-officer-6707346)
- 2026-09-01 13:00 UTC [Conference Announcement] [Editas Medicine to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/editas-medicine-to-participate-in-upcoming-investor-conferences-6700806)
- 2026-08-31 20:25 UTC [SEC Form S-3] [SEC Form S-3 filed by Editas Medicine Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-editas-medicine-inc-6699862)
- 2026-08-18 12:23 UTC [Analyst Coverage Initiated] [Ladenburg Thalmann initiated coverage on Editas Medicine with a new price target](https://www.quantisnow.com/insight/ladenburg-thalmann-initiated-coverage-on-editas-medicine-with-a-new-6685971)
- 2026-08-07 21:16 UTC [SEC Form 4] [SEC Form 4 filed by Director Ellinor Patrick Thomas Ii](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ellinor-patrick-thomas-ii-6672126)
- 2026-08-07 21:15 UTC [SEC Form 3] [SEC Form 3 filed by new insider Ellinor Patrick Thomas Ii](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-ellinor-patrick-thomas-6672124)
- 2026-08-05 20:07 UTC [SEC Form 4] [SVP, Chief Financial Officer Parison Amy sold $1,749 worth of shares (678 units at $2.58), decreasing direct ownership by 5% to 14,292 units (SEC Form 4) to cover withholding tax](https://www.quantisnow.com/insight/svp-chief-financial-officer-parison-amy-sold-1749-worth-of-6665200)
- 2026-08-05 20:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Editas Medicine Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-editas-medicine-inc-6665069)
- 2026-08-05 20:03 UTC [SEC Form 8-K] [Editas Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/editas-medicine-inc-filed-sec-form-8-k-results-of-operations-6664846)
- 2026-08-05 20:01 UTC [Public Offering] [Editas Medicine Announces Second Quarter 2026 Results and Business Updates](https://www.quantisnow.com/insight/editas-medicine-announces-second-quarter-2026-results-and-business-updates-6664754)
- 2026-08-04 20:15 UTC [Leadership Update] [Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.](https://www.quantisnow.com/insight/editas-medicine-strengthens-board-of-directors-with-appointment-of-patrick-6662302)
- 2026-07-29 20:51 UTC [SEC Form 4] [EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold $13,158 worth of shares (4,928 units at $2.67), decreasing direct ownership by 7% to 62,369 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/evp-chief-scientific-officer-burkly-linda-sold-13158-worth-of-6654172)
- 2026-06-22 20:31 UTC [SEC Form 4] [SEC Form 4 filed by Director Connaughton Bernadette](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-connaughton-bernadette-6610931)
- 2026-06-22 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Hopfield Jessica](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hopfield-jessica-6610921)
- 2026-06-22 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Hirsch Andrew](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hirsch-andrew-6610909)
- 2026-06-22 20:29 UTC [SEC Form 4] [SEC Form 4 filed by Director Scadden David](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-scadden-david-6610903)
- 2026-06-22 20:28 UTC [SEC Form 4] [SEC Form 4 filed by Director Levy Elliott M.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-levy-elliott-m-6610898)
- 2026-06-18 20:28 UTC [SEC Form 8-K] [Editas Medicine Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/editas-medicine-inc-filed-sec-form-8-k-submission-of-matters-6608967)
- 2026-06-05 20:33 UTC [SEC Form 4] [SVP, Chief Financial Officer Parison Amy sold $1,253 worth of shares (464 units at $2.70), decreasing direct ownership by 3% to 14,970 units (SEC Form 4) to satisfy tax liability](https://www.quantisnow.com/insight/svp-chief-financial-officer-parison-amy-sold-1253-worth-of-6591591)
- 2026-06-05 20:33 UTC [SEC Form 4] [CEO O'Neill Gilmore Neil sold $41,543 worth of shares (15,380 units at $2.70), decreasing direct ownership by 6% to 248,313 units (SEC Form 4) (for withholding tax)](https://www.quantisnow.com/insight/ceo-oneill-gilmore-neil-sold-41543-worth-of-shares-15380-6591587)
- 2026-06-05 20:32 UTC [SEC Form 4] [EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold $1,975 worth of shares (731 units at $2.70), decreasing direct ownership by 1% to 67,297 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/evp-chief-scientific-officer-burkly-linda-sold-1975-worth-of-6591577)
- 2026-06-03 20:45 UTC [SEC Form SCHEDULE 13G filed by Editas Medicine Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-editas-medicine-inc-6587427)
- 2026-05-28 20:01 UTC [Conference Announcement] [Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference](https://www.quantisnow.com/insight/editas-medicine-announces-updated-presentation-time-for-upcoming-investor-conference-6576892)
- 2026-05-26 21:30 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Editas Medicine Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-editas-medicine-inc-6573086)
- 2026-05-26 20:42 UTC [SEC Form 8-K] [Editas Medicine Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/editas-medicine-inc-filed-sec-form-8-k-entry-into-a-6572714)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/EDIT
- Earnings history: https://www.quantisnow.com/earnings/EDIT
- Dividend history: https://www.quantisnow.com/dividends/EDIT
- Insider transactions: https://www.quantisnow.com/insiders/EDIT
- Options chain: https://www.quantisnow.com/options/EDIT
- SEC 8-K filings only: https://www.quantisnow.com/company/EDIT/8-k
- RSS and alerts for EDIT: https://www.quantisnow.com/docs/rss-feeds.md